Sorafenib: Activity and clinical application in patients with hepatocellular carcinoma

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 2, 2011, Pages 303-313

  Guan, Yong Song ^a   He, Qing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoM.A.; Mechanism; Sorafenib; Targeted therapy; Treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; RAF PROTEIN; RIFAMPICIN; SORAFENIB;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DESQUAMATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; ENZYME INHIBITION; EX VIVO STUDY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUMOR VASCULARIZATION; VOICE CHANGE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 78651412820     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.546346     Document Type: Article

References (71)

1. Sandhu DS, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:81-92
2. Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg 2006;10:761-80
3. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeons perspective. Ann Surg 2002;235:466-86 (Pubitemid 34258345)
4. Rayya F, Harms J, Bartels M, et al. Results of resection and transplantation for hepatocellular carcinoma in cirrhosis and noncirrhosis. Transplant Proc 2008;40:933-5 (Pubitemid 351794300)
5. Chaparro M, Gonzalez Moreno L, Trapero-Marugan M, et al. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008;28:1269-77
6. Ng R, Chen EX. Curr. Sorafenib (BAY 43-9006): review of clinical development. Clin Pharmacol 2006;1:223-8
7. Caraglia M, Tassone P, Marra M, et al. Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 2006;17(Suppl 7):vii124-127 (Pubitemid 43994853)
8. Chia WJ, Tang BL. Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta 2009;1795:110-16
9. Papageorge AG, Defeo-Jones D, Robinson P, et al. Mol. Saccharomyces cerevisiae synthesizes proteins related to the p21 gene product of ras genes found in mammals. Cell Biol 1984;4:23-9 (Pubitemid 14180046)
10. Williams NG, Roberts TM. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev 1994;13:105-16 (Pubitemid 24053342)
11. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009;4:28-35
12. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 2005;31:151-74 (Pubitemid 41306584)
13. Boulton TG, Nye SH, Robbins DJ, et al. ERKs: a family of protein-serine/ threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663-75
14. Cobb MH, Hepler JE, Cheng M, Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol 1994;5:261-8 (Pubitemid 124006796)
15. Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997;14:1635-42 (Pubitemid 27198935)
16. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310 (Pubitemid 46763022)
17. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-6
18. Ria R, Vacca A, Russo F, et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004;92:1438-45 (Pubitemid 39642557)
19. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40
20. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406 (Pubitemid 44142735)
21. Ueda M, Toji E, Nunobiki O, et al. Mutational analysis of the BRAF gene in human tumor cells. Hum Cell 2008;21:13-7 (Pubitemid 351499179)
22. Halilovic E, Solit DB. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 2008;8:419-26
23. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100
24. Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 2007;4:741-56 (Pubitemid 350261440)
25. Rozengurt E. Mol. Growth factors, cell proliferation and cancer: an overview. Biol Med 1983;1:169-81 (Pubitemid 14143209)
26. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005;41:773-84 (Pubitemid 43333354)
27. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37 (Pubitemid 46698720)
28. Minami H, Kawada K, Ebi H, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008;99:1492-8 (Pubitemid 351761743)
29. Akaza H, Tsukamoto T, Murai M, et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62 (Pubitemid 350120299)
30. Lencioni R, Marrero J, Venook A, et al. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010;64(8):1034-41
31. Llanos L, Bellot P, Zapater P, et al. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. Am J Gastroenterol 2009;104:257-8
32. Wei L, Huang N, Yang L, et al. Sorafenib reverses multidrug resistance of hepatoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2009;29:1016-19
33. Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280:35217-27 (Pubitemid 41532709)
34. Reynolds JE, Yang T, Qian L, et al. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994;54:6348-52
35. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8 (Pubitemid 46094197)
36. Wei L, Su N, Zheng DY, et al. Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009;25:344-7
37. Shiota M, Eto M, Yokomizo A, et al. Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation. Int J Oncol 2010;37(2):509-17
38. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
39. Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009;29:10-17
40. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94 (Pubitemid 41510145)
41. Richly H, Kupsch P, Passage K, et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004;42:650-1
42. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300 (Pubitemid 46630787)
43. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
44. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
45. Abou-Alfa GK. Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Netw 2009;7:397-403
46. Sorafenib. gastrointestinal perforation. Prescrire Int 2009;18:69 PMID: 19585726
47. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-54 (Pubitemid 32202552)
48. Almhanna K, Philip PA. Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther 2009;2:261-7
49. Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008;26:3665-7
50. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-48
51. Li XM, Tang ZY, Qin LX, et al. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 1999;18:511-17 (Pubitemid 30114740)
52. Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009;100:1385-92
53. Worns MA, Weinmann A, Schuchmann M, Galle PR. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009;27:175-88
54. Chen FS, Cui YZ, Luo RC, et al. Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1684-7
55. Wu J, Luo RC, Zhang H, Cui YZ. Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:639-41
56. Simpson D, Keating GM. Sorafenib: in hepatocellular carcinoma. Drugs 2008;68:251-8
57. Muszbek N, Shah S, Carroll S, et al. Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Curr Med Res Opin 2008;24:3559-69
58. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27
59. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008;75(Suppl 1):1-12
60. Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, et al. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 2008;7:82
61. Detry O, Delwaide J, De Roover A, et al. Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial). Rev Med Liege 2009;64:168-70
62. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14:70-6
63. Tremosini S, Reig M, de Lope CR, et al. Treatment of early hepatocellular carcinoma: towards personalized therapy. Dig Liver Dis 2010;42(Suppl 3):S242-248
64. Zender L, Villanueva A, Tovar V, et al. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-9
65. Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010;42(Suppl 3):S235-41
66. Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am 2010;90:803-16
67. Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009;9:2851-4
68. Lencioni R, Marrero J, Venook A, et al. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010;64:1034-41
69. Yoon DH, Ryoo BY, Ryu MH, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010;40:768-73
70. Biolato M, Marrone G, Racco S, et al. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci 2010;14:356-62
71. Zhao JD, Liu J, Ren ZG, et al. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/ intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol 2010;5:12